JAMA Surg 2024;159:660-7.ArticlePubMedPMC 20
Among 173 RA patients with overweight or obesity who were prescribed GLP-1 agonists and actually took them, 32% showed improvement in RA disease activity after 1 year, compared with 17% of 42 patients who were also prescribed the drugs but never started them, according to Veena Ranganath, MD, MS, of the University of California Los Angeles (UCLA), and colleagues
The historical tendency to equate pleiotropy with risk rather than opportunity appears increasingly outdated in light of contemporary successes with multi-agonist and network-based therapies
The mid-2025 complaint pattern (orders delayed 2+ weeks, tickets unanswered for 8 days or more) suggests this standard slips during demand spikes
No side effects and great shipping
Weight loss accelerates, with many users losing 3 to 4 pounds weekly during dose increases